Skip to main content
Clinical Trials/IRCT20100107003014N26
IRCT20100107003014N26
Recruiting
Phase 1

Comparison the efficacy of adding levofloxacin and colistin inhalation form to basic regimen of colistin and meropenem in treatment of ventilator associated pneumonia (VAP) caused by multidrug resistant pathogens: a double-blind randomized clinical trial

Mazandaran University of Medical Sciences0 sites70 target enrollmentTBD

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
Ventilator associated pneumonia (VAP) caused by multidrug resistant pathogens.
Sponsor
Mazandaran University of Medical Sciences
Enrollment
70
Status
Recruiting
Last Updated
2 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
2 years ago
Study Type
Interventional
Sex
All

Investigators

Eligibility Criteria

Inclusion Criteria

  • Age older than 18 years and less than 80 years
  • Mechanical ventilation for more than 48 hours
  • Pneumonia diagnosis based on the 2016 guidelines of the Infectious Diseases Society of America (IDSA)
  • CPIS score above 6
  • Positive culture of sputum sample and growth of gram\-negative bacteria resistant to treatment (MDR) (Acinetobacter baumannii, Pseudomonas aeruginosa, Enterobacteriaceae, etc.)

Exclusion Criteria

  • Pregnancy or breastfeeding
  • History of allergy to any of the drugs Colistin, Levofloxacin and Meropenem
  • Acute respiratory distress syndrome
  • Pulmonary tuberculosis disease under treatment
  • Cystic fibrosis disease
  • Major interaction of other drugs used by the patient with levofloxacin, colistin or meropenem
  • Baseline creatinine clearance less than 15 mL/min
  • History of receiving antibiotics effective against MDR pathogens during hospitalization
  • Presence of pneumonia before intubation

Outcomes

Primary Outcomes

Not specified

Similar Trials